FIELD: biotechnology.
SUBSTANCE: antibodies to CCR7, their antigen-binding fragments, and antibody-drug conjugates based on the specified antibodies or antigen-binding fragments are proposed. The invention also relates to pharmaceutical compositions and methods for the treatment or prevention of cancer, using the specified antibodies, antigen-binding fragments, and conjugates. In addition, nucleic acids, expression vectors, and host cells for the production of antibodies are disclosed.
EFFECT: invention can be used in cancer therapy in the absence of significant depletion of normal hemopoietic cells expressing CCR7.
40 cl, 22 dwg, 27 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIBODIES SPECIFIC FOR CD70 AND THEIR USE | 2019 |
|
RU2801093C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
